Role of Community Pharmacist Care and Management Diabetic Neuropathatic Patients
Abstract
Pharmacist is currently turning further into a patient minded than product tilted and have brought several changes in lifetime of patients. There are substantial proofs that patient’s psychotherapy enhances patient conformity and advance the standard of life effect in diabetic patients. Diabetic neuropathy could be a kind of nerve injury that is seen in people that have diabetes. This makes it difficult for the nerves to carry messages to the brain and parts of the body. Diabetic neuropathy can influence any fraction of the nervous system. This nerve disorder ought to be alleged in all patients with type 2 diabetes and in sufferers who’ve had type 1 diabetes for greater than 5 years. About 60 to 70 percent of human beings with diabetes have a little type of neuropathy. People with diabetes can develop nerve problems at any time, but the risk increases with age and duration of the disease. The highest rates of neuropathy occur among people who have had diabetes for as a minimum 25 years and among humans who’ve hassle controlling their blood sugar levels, as well as the ones with excessive degrees of blood fat and blood pressure and people who are overweight. Diabetic
neuropathy is long-term damage to the nerve fibers. It happens when high blood glucose levels are present over several years. In diabetes, the form it usually first takes is reduced sensation in the feet. The nerve harm influences each foot equally and in the end extends up the legs. Poor consciousness in your feet makes them extra at risk of injury. Combined with terrible circulation this could easily cause ulcers and infections. As community Pharmacist becomes a consultant for patients who are put on therapy. He counsels the patients about the disease process and simultaneously role of drugs. He informs the patient of drug interactions and adverse reactions.
How to cite this article: Rastogi C, Verma P, Raj A et al. Role of Community Pharmacist Care and Management Diabetic Neuropathatic Patients. Int J Adv Res Pharm Edu 2019; 1(1): 9-14.
References
Greene DA, Sima AF, Pfeifer MA et al. Diabetic neuropathy. Annu Rev Med 1990; 41: 303-317.
Olaleye D, Perkins BA, Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract 2001; 54: 115-128.
Vinik AI, Maser RE, Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-1579.
Stevens MJ, Raffel DM, Allman KC et al. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism 1999; 48: 92-101.
Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. American Diabetes Association Diabetes Care 1998; 21: 1551-1559.
May O, Arildsen H. Assessing cardiovascular autonomic neuropathy in diabetes mellitus: how many tests to use? J Diabetes Complications 2000; 14: 7-12.
Frykberg RG, Armstrong DG, Giurini J et al. Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. J Foot Ankle Surg 2000; 395: S1-60.
Sommer TC, Lee TH. Charcot foot: the diagnostic dilemma [published correction appears in Am Fam Physician 2002;65:2436-8]. Am Fam Physician. 2001;64:1591-8.
Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc 1993; 68: 691-702.
Wald A. Incontinence and anorectal dysfunction in patients with diabetes mellitus. Eur J Gastroenterol Hepatol 1995; 7: 737-739.
Chu NV, Edelman SV. Erectile dysfunction and diabetes. Curr Diab Rep 2002; 2: 60-66.
Minhas S, Eardley I. Diabetes mellitus and impotence. In: Carson CC 3d, Kirby RS, Goldstein I, eds. Textbook of erectile dysfunction. Oxford, England: Isis Medical Media. 1999: 541-550.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet
;354:602]. Lancet 1998; 352: 837-853.
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 1: S4-36.
Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38: 869-880.
American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self management 2002 update. Endocrine Practice 2002; 8: 41-65.
Hollingshead TS. Pathophysiology and treatment of diabetic foot ulcer. Clin Podiatr Med Surg 1991; 8: 843-855.
Armstrong DG, Lavery LA. Diabetic foot ulcers: prevention, diagnosis and classification. Am Fam Physician 1998; 57: 1325-3213.
Mayfield JA, Reiber GE, Sanders LJ et al. American Diabetes Association. Preventive foot care in diabetes. Diabetes Care 2004; 27: S63-S64.
National Diabetes Education Program. Feet can last a lifetime. Screening form for diabetes foot disease. 2005, at: http://ndep.nih.gov/resources/feet/screenfo.htm.
Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician 2002; 66: 1655-1662.
